SCHEMBL6924627

SCHEMBL6924627

NCCCOCC(COCCCN)(COCCCN)COCCCN

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ODC1 P11926 1/20 0.43
CYP3A4 P08684 1/20 0.34
NFKB1 P19838 1/20 0.33
CA12 O43570 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA3 P07451 2/20 0.32
CA4 P22748 2/20 0.32
CA6 P23280 2/20 0.32
CA5A P35218 2/20 0.32
CA7 P43166 2/20 0.32
CA9 Q16790 2/20 0.32
CA14 Q9ULX7 2/20 0.32
CA5B Q9Y2D0 2/20 0.32
DNM1 Q05193 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12317015 0.95 ODC1 (0.39) ODC1CYP3A4NFKB1
SCHEMBL16807587 0.92 NFKB1 (0.39) ODC1NFKB1CA12CA1CA2
SCHEMBL19655569 0.88 CYP3A4 (0.46) ODC1CYP3A4DNM1TSHR
Ammonia Solution, Strong SCHEMBL14860334 0.86 CYP3A4 (0.40) ODC1CYP3A4DNM1TSHR
SCHEMBL6885240 0.85 THRB (0.40) ODC1CYP3A4DNM1TSHR
SCHEMBL12201021 0.85 CYP3A4 (0.38) ODC1CYP3A4DNM1TSHR
SCHEMBL15146724 0.85 ODC1 (0.36) ODC1CYP3A4
SCHEMBL11965457 0.81
SCHEMBL13574313 0.81
SCHEMBL15697257 0.81 LMNA (0.46) ODC1NFKB1LMNATSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366490-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN INC (US) 2024-11-07 US claimed
US-20220370323-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. 2022-11-24 US claimed
US-20200352843-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. 2020-11-12 US claimed
US-10758470-B2 Cross linked silk-hyaluronic acid composition ALLERGAN, INC. (US) 2020-09-01 US claimed
EP-2988791-B1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN INC (US) 2019-06-12 EP claimed
US-10154951-B2 Cross linked silk-hyaluronic acid composition ALLERGAN, INC. (US) 2018-12-18 US claimed
US-20180303742-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. 2018-10-25 US claimed
US-20160361247-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. 2016-12-15 US claimed
EP-2988791-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. (US) 2016-03-02 EP claimed
WO-2014176158-A1 CROSS LINKED SILK-HYALURONIC ACID COMPOSITION ALLERGAN, INC. (US) 2014-10-30 WO claimed
US-20140315828-A1 CROSS-LINKED SILK-HYALURONIC ACID COMPOSITIONS ALLERGAN, INC. (US) 2014-10-23 US claimed
EP-2787959-A2 DERMAL FILLER COMPOSITIONS ALLERGAN, INC. (US) 2014-10-15 EP claimed
WO-2013086024-A2 DERMAL FILLER COMPOSITIONS ALLERGAN, INC. (US) 2013-06-13 WO claimed
US-20130096081-A1 DERMAL FILLER COMPOSITIONS ALLERGAN, INC. (US) 2013-04-18 US claimed
US-20250340675-A1 NEW HYALURONIC ACID DERIVATIVES AS INNOVATIVE FILLERS WiQo S.P.A. (IT) 2025-11-06 US disclosed
US-12458582-B2 Stabilized hyaluronic acid CROMA-PHARMA GMBH (AT) 2025-11-04 US disclosed
EP-4578462-A2 DERMAL FILLER COMPOSITIONS ALLERGAN Industrie, SAS (FR) 2025-07-02 EP disclosed
WO-2000076760-A1 POLYMERIC MEMBRANES FUNCTIONALIZED WITH POLYHYDROXYPYRIDINONE LIGANDS IBC ADVANCED TECHNOLOGIES, INC. (US) 2000-12-21 WO disclosed
WO-2000076616-A1 PARTICULATE SOLID SUPPORTS FUNCTIONALIZED WITH POLYHYDROXYPYRIDINONE LIGANDS IBC ADVANCED TECHNOLOGIES, INC. (US) 2000-12-21 WO disclosed
US-4383107-A POLYTRIAZINES; CURABLE; CASTINGS; ADHESIVES; FOAMS CIBA-GEIGY CORPORATION (US) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458582-B2 Stabilized hyaluronic acid CD44, HSPH1, ACR ODC1 4466/4885CYP3A4 4267/4885NFKB1 3685/4885
US-20250340675-A1 NEW HYALURONIC ACID DERIVATIVES AS INNOVATIVE FILLERS CD44, MMP1, HAAO ODC1 3633/4885CYP3A4 1019/4885NFKB1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.